LONDON, Aug 13 (Reuters) - Baxalta wants Shire to improve on its $30 billion bid significantly before it will engage in talks, while its Dublin-based rival could sweeten its offer if it gets to see the U.S. biotech company's books, according to sources on both sides.
from Reuters: New Issues News http://ift.tt/1DPNUR8
Tidak ada komentar:
Posting Komentar